Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Mikhael

Showing results (71-80 of 104) with videos related to

Pageof 11
Sort By:
American Journal of Hematology|May 23, 2022
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysisMeletios A Dimopoulos, Philippe Moreau, Bradley Augustson, et al.
Blood Cancer Journal|November 28, 2024
Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studiesPaul G Richardson, Aurore Perrot, Joseph Mikhael, et al.
British Journal of Haematology|May 25, 2019
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myelomaAndrzej J Jakubowiak, Jagoda K Jasielec, Cara A Rosenbaum, et al.
Leukemia|May 16, 2020
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myelomaJoseph Mikhael, Joshua Richter, Ravi Vij, et al.
Future Oncology (London, England)|June 27, 2026
Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasoneKwee Yong, Thomas Martin, Meletios-Athanasios Dimopoulos, et al.
Blood Cancer Journal|May 8, 2023
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 studyThomas Martin, Meletios-Athanasios Dimopoulos, Joseph Mikhael, et al.
Lancet (London, England)|June 7, 2021
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trialPhilippe Moreau, Meletios-Athanasios Dimopoulos, Joseph Mikhael, et al.
Blood|June 11, 2014
Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myelomaYuan Xiao Zhu, Esteban Braggio, Chang-Xin Shi, et al.
Blood Cancer Journal|September 26, 2023
Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 studyThomas Martin, Meletios-Athanasios Dimopoulos, Joseph Mikhael, et al.
The Lancet. Haematology|July 27, 2024
Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trialKwee Yong, Thomas Martin, Meletios-Athanasios Dimopoulos, et al.
Pageof 11

Showing results (71-80 of 104) with videos related to

Sort By:
Pageof 11
American Journal of Hematology|May 23, 2022
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysisMeletios A Dimopoulos, Philippe Moreau, Bradley Augustson, et al.
Blood Cancer Journal|November 28, 2024
Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studiesPaul G Richardson, Aurore Perrot, Joseph Mikhael, et al.
British Journal of Haematology|May 25, 2019
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myelomaAndrzej J Jakubowiak, Jagoda K Jasielec, Cara A Rosenbaum, et al.
Leukemia|May 16, 2020
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myelomaJoseph Mikhael, Joshua Richter, Ravi Vij, et al.
Future Oncology (London, England)|June 27, 2026
Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasoneKwee Yong, Thomas Martin, Meletios-Athanasios Dimopoulos, et al.
Blood Cancer Journal|May 8, 2023
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 studyThomas Martin, Meletios-Athanasios Dimopoulos, Joseph Mikhael, et al.
Lancet (London, England)|June 7, 2021
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trialPhilippe Moreau, Meletios-Athanasios Dimopoulos, Joseph Mikhael, et al.
Blood|June 11, 2014
Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myelomaYuan Xiao Zhu, Esteban Braggio, Chang-Xin Shi, et al.
Blood Cancer Journal|September 26, 2023
Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 studyThomas Martin, Meletios-Athanasios Dimopoulos, Joseph Mikhael, et al.
The Lancet. Haematology|July 27, 2024
Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trialKwee Yong, Thomas Martin, Meletios-Athanasios Dimopoulos, et al.
Pageof 11